168 related articles for article (PubMed ID: 28771887)
1. ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells.
Migita T; Takayama KI; Urano T; Obinata D; Ikeda K; Soga T; Takahashi S; Inoue S
Cancer Sci; 2017 Oct; 108(10):2011-2021. PubMed ID: 28771887
[TBL] [Abstract][Full Text] [Related]
2. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
3. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Park S; Song CS; Lin CL; Jiang S; Osmulski PA; Wang CM; Marck BT; Matsumoto AM; Morrissey C; Gaczynska ME; Chen Y; Mostaghel EA; Chatterjee B
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31894239
[TBL] [Abstract][Full Text] [Related]
6. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
Yenki P; Bhasin S; Liu L; Nabavi N; Cheng CW; Tam KJ; Peacock JW; Adomat HH; Tombe T; Fazli L; Ivanova L; Dusek C; Khosravi S; Guns EST; Wang Y; Buttyan R; Gleave ME; Ong CJ
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37800655
[TBL] [Abstract][Full Text] [Related]
7. AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol.
Detlefsen AJ; Mesaros CA; Duan L; Penning TM
Cancer Res Commun; 2023 Sep; 3(9):1888-1898. PubMed ID: 37772993
[TBL] [Abstract][Full Text] [Related]
8. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
[No Abstract] [Full Text] [Related]
9. Crystal structure determination, molecular docking, and molecular dynamics of arylal dimedones as potential inhibitors for castrate-resistant prostate cancer.
R C; Kiran KS; Chaithanya MS; M A
Biotechnol Appl Biochem; 2023 Dec; 70(6):1794-1805. PubMed ID: 37279111
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer.
Pippione AC; Kovachka S; Vigato C; Bertarini L; Mannella I; Sainas S; Rolando B; Denasio E; Piercy-Mycock H; Romalho L; Salladini E; Adinolfi S; Zonari D; Peraldo-Neia C; Chiorino G; Passoni A; Mirza OA; Frydenvang K; Pors K; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
Eur J Med Chem; 2024 Mar; 268():116193. PubMed ID: 38364714
[TBL] [Abstract][Full Text] [Related]
11. Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model.
Maddeboina K; Jonnalagadda SK; Morsy A; Duan L; Chhonker YS; Murry DJ; Penning TM; Trippier PC
J Med Chem; 2023 Jul; 66(14):9894-9915. PubMed ID: 37428858
[TBL] [Abstract][Full Text] [Related]
12. New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis.
Castillo AF; Orlando UD; Maloberti PM; Prada JG; Dattilo MA; Solano AR; Bigi MM; Ríos Medrano MA; Torres MT; Indo S; Caroca G; Contreras HR; Marelli BE; Salinas FJ; Salvetti NR; Ortega HH; Lorenzano Menna P; Szajnman S; Gomez DE; Rodríguez JB; Podesta EJ
Cell Mol Life Sci; 2021 Mar; 78(6):2893-2910. PubMed ID: 33068124
[TBL] [Abstract][Full Text] [Related]
13. Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader.
Carmona AV; Jonnalagadda S; Case AM; Maddeboina K; Jonnalagadda SK; Dow LF; Duan L; Penning TM; Trippier PC
Commun Chem; 2024 Apr; 7(1):95. PubMed ID: 38684887
[TBL] [Abstract][Full Text] [Related]
14. 5-Hydroxyeicosatetraenoic Acid Controls Androgen Reduction in Diverse Types of Human Epithelial Cells.
Hardaway AL; Goudarzi M; Berk M; Chung YM; Zhang R; Li J; Klein E; Sharifi N
Endocrinology; 2022 Nov; 164(1):. PubMed ID: 36412122
[TBL] [Abstract][Full Text] [Related]
15. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.
Dalal K; Che M; Que NS; Sharma A; Yang R; Lallous N; Borgmann H; Ozistanbullu D; Tse R; Ban F; Li H; Tam KJ; Roshan-Moniri M; LeBlanc E; Gleave ME; Gewirth DT; Dehm SM; Cherkasov A; Rennie PS
Mol Cancer Ther; 2017 Oct; 16(10):2281-2291. PubMed ID: 28775145
[TBL] [Abstract][Full Text] [Related]
16. ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression.
Rossi Sebastiano M; Pozzato C; Saliakoura M; Yang Z; Peng RW; Galiè M; Oberson K; Simon HU; Karamitopoulou E; Konstantinidou G
Sci Adv; 2020 Oct; 6(44):. PubMed ID: 33127675
[TBL] [Abstract][Full Text] [Related]
17. The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer.
Saliakoura M; Reynoso-Moreno I; Pozzato C; Rossi Sebastiano M; Galié M; Gertsch J; Konstantinidou G
Oncogene; 2020 Apr; 39(14):2948-2960. PubMed ID: 32034305
[TBL] [Abstract][Full Text] [Related]
18. Long-Chain Acyl-CoA Synthetase 4-Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway-Independent Prostate Cancer.
Ma Y; Zhang X; Alsaidan OA; Yang X; Sulejmani E; Zha J; Beharry Z; Huang H; Bartlett M; Lewis Z; Cai H
Mol Cancer Res; 2021 Jan; 19(1):124-135. PubMed ID: 33077484
[TBL] [Abstract][Full Text] [Related]
19. Metabolic enzyme ACSL3 is a prognostic biomarker and correlates with anticancer effectiveness of statins in non-small cell lung cancer.
Fernández LP; Merino M; Colmenarejo G; Moreno-Rubio J; Sánchez-Martínez R; Quijada-Freire A; Gómez de Cedrón M; Reglero G; Casado E; Sereno M; Ramírez de Molina A
Mol Oncol; 2020 Dec; 14(12):3135-3152. PubMed ID: 33030783
[TBL] [Abstract][Full Text] [Related]
20. The endogenous subcellular localisations of the long chain fatty acid-activating enzymes ACSL3 and ACSL4 in sarcoma and breast cancer cells.
Radif Y; Ndiaye H; Kalantzi V; Jacobs R; Hall A; Minogue S; Waugh MG
Mol Cell Biochem; 2018 Nov; 448(1-2):275-286. PubMed ID: 29450800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
